Glycosyl sulfotransferase-3
AssigneesThe Regents of the University of California, Syntex (U.S.A.) Inc.
InventorsAnnette Bistrup, Steven D. Rosen, Kirsten Tangemann, Stefan Hemmerich
Life of this patent
Estimating the term…
Abstract
A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of GST-3 or KSGal6ST, or homologues thereof.
Claims29
Glycosyl sulfotransferase-3 present in other than its natural environment.
A nucleic acid present in other than its natural environment, wherein said nucleic acid has a nucleotide sequence encoding glycosyl sulfotransferase-3.
A monoclonal antibody binding specifically to glycosyl sulfotransferase-3.
A method for inhibiting a binding event between a selectin and a selectin ligand, said method comprising:
- contacting said selectin with a non-sulfated selectin ligand, a sulfotransferase selected from the group consisting of glycosyl sulfotransferase-3 and KSGal6ST, and an agent that inhibits the sulfation activity of said sulfotransferase.
A method of inhibiting a selectin mediated binding event in a mammalian host, said method comprising:
- administering to said host an effective amount of a pharmaceutical composition comprising an active agent that modulates the sulfation activity of a sulfotransferase selected from the group consisting of GST-3 and KSGal6ST and homologues thereof.
A method of modulating a symptom in a mammalian host of a disease condition associated with a selectin mediated binding event, said method comprising:
- administering to said host a pharmaceutical composition comprising an effective amount of an active agent that modulates the sulfation activity of a sulfotransferase selected from the group consisting of GST-3 and KSGal6ST and homologues thereof.
A method of diagnosing a disease state in a host related to the abnormal levels of sulfotransferase selected from the group consisting of glycosyl sulfotransferase-3 and KSGal6ST, said method comprising:
- determining the amount of an analyte in a sample from said host, wherein said analyte is selected from the group consisting of said sulfotransferase or a nucleic acid related thereto;
- and
- comparing the amount of said analyte in said host sample to a control value.
A method of determining whether an agent is capable of modulating the activity of a sulfotransferase selected from the group consisting of glycosylsulfotransferase-3 and KSGal6ST, said method comprising:
- contacting a sulfotransferase with a sulfate source, an acceptor compound and said agent;
- and
- determining the affect of said agent on said sulfotransferase activity.
A non-human transgenic animal model for Gst-3 gene function wherein said transgenic animal comprises an introduced alteration in a Gst-3 gene.
Dependencies are inferred from the claim text.